Cure8 research brief
The study provides real-world effectiveness and safety data for risankizumab in a largely difficult-to-treat Crohn's population, showing about half achieved corticosteroid-free clinical remission at 24 weeks — information that may influence treatment decisions for patients with prior biologic or advanced therapy failures.
Adult Crohn's disease patients (especially those with difficult-to-treat disease or prior biologic failure), clinicians prescribing biologics, and researchers studying real-world biologic outcomes.
This study used the Dutch Initiative on Crohn and Colitis Registry to follow 151 patients who started risankizumab, most (90%) classified as difficult-to-treat (prior failure of advanced therapies with ≥2 mechanisms). The primary outcome was corticosteroid-free clinical remission (Harvey-Bradshaw Index ≤4) at week 24.
About half of patients achieved corticosteroid-free clinical remission at week 24 (≈50–53% depending on analytic subgroup). Discontinuation occurred in 14.6%, mainly for nonresponse; adverse events possibly or probably related to risankizumab were reported and quantified per 100 person-years.
This is an observational registry study; it reports associations and outcomes in routine practice rather than randomized comparisons. Rates and safety signals should be interpreted in the context of study design and patient characteristics.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Guidelines recommend treating objective inflammation even when symptoms are mild because untreated disease can cause complications; the article describes escalation to risankizumab due to endoscopic inflammation, high...
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
This real-world, multicenter study suggests risankizumab can induce clinical and steroid-free remission and mucosal healing in many patients with Crohn disease who previously failed advanced therapies, which may be...
